

TRISTEL plc
("Tristel" or the "Company")

Confirmation of Interim Results
Analyst & Investor briefing schedule

Tristel plc (AIM: TSTL), the manufacturer of infection prevention products, confirms it will hold the following briefings with respect to its interim results for the six-month period ended 31 December 2024 on Monday 24 February 2025.

Analyst briefing

A briefing open to analysts will take place in London on Monday 24 February 2025 at 10am. To register and for more details please contact Walbrook PR on tristel@walbrookpr.com

Investor presentation

Matt Sassone, CEO, and Liz Dixon, CFO, will present the Company's results in two separate events open to all investors. The same presentation will be given at both events which are being held at different times to offer convenient options for those wishing to attend.

Two presentations will take place on Monday 24 February 2025 at the following times, the first will be held online via the Investor Meet Company platform and the second will be held in-person in the City of London, full details below:

1. Investor Meet Company online presentation

Tristel management will provide a live online presentation relating to the interim results via Investor Meet Company at 11.30am. The presentation is open to all existing and potential shareholders. Questions can be submitted pre-event via your Investor Meet Company dashboard up until 9am the day before the meeting or at any time during the live presentation.

Investors can sign up to Investor Meet Company for free and add to meet Tristel plc via:

<https://www.investormeetcompany.com/tristel-plc/register-investor>

2. In-person investor presentation

Tristel management will provide an in-person presentation relating to the Company's interim results at 4.30pm, which is open to all existing and potential shareholders. The Company welcomes investors to 85 Gresham Street, London, EC2V 7NQ from 4.15pm for a 4.30pm start and will be followed by refreshments.

If you would like to attend, please contact Walbrook PR on 020 7933 8780 or email tristel@walbrookpr.com.

The results presentation will be made available on the Company's website on the day of results www.investors.tristel.com

For further information please contact:

Tristel plc

Matt Sassone, Chief Executive Officer
Liz Dixon, Chief Financial Officer

Via Walbrook PR
www.investors.tristel.com

Walbrook PR Ltd

Paul McManus / Lianne Applegarth / Alice Woodings

Tel: 020 7933 8780 or tristel@walbrookpr.com
Mob: 07980 541 893/ 07584 391 303/ 07407 804 654

Cavendish Capital Markets Ltd

Geoff Nash / Camilla Hume / Trisyia Jamaludin (Corporate Finance)
Sunila de Silva (ECM) / Louise Talbot (Sales)

Tel: 020 7220 0500

About Tristel plc

Tristel plc is a global infection prevention company focussed on the manufacture and supply of products using its unique proprietary chlorine dioxide (ClO₂) chemistry. The Company is a market leader in manual decontamination of medical devices, supplying hospitals under the [Tristel](#) brand, and under the [Cache](#) brand provides products for sporicidal surface disinfection, a more sustainable alternative to commonly used pre-wetted plastic wipes.

Tristel's head office and manufacturing facility is located in Snailwell, near Cambridge, and operates globally employing approximately 270 people across 16 subsidiaries selling into 40+ countries. The Company targets annual revenue growth of between 10% and 15% and an EBITDA margin of at least 25% and the business is profitable, with no debt and has a progressive dividend policy.

The Company has been listed on the London Stock Exchange's AIM market since 2005 (AIM: TSTL).

For more information about Tristel's product range please visit: <https://tristel.com>

Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact ms@seg.com or visit www.ms.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

NORPKKBQDBKDFDD